Long-Term Mesothelioma Survival with ONCOS-102
The makers of the immunotherapy treatment ONCOS-102 have released promising new data on its ability to promote long-term mesothelioma survival. The report came less than two weeks after ONCOS-102 got FDA approval to fast-track its development. ONCOS-102 is an investigational treatment made from a modified virus. The virus helps the treatment target mesothelioma cells while leaving healthy cells alone. The new long-term mesothelioma survival data shows half of people on ONCOS-102 and chemotherapy have lived for 21 months. And the study is not over yet. Typical survival with standard mesothelioma chemotherapy is about a year. Targovax says the data shows how valuable ONCOS-102 could be for patients with this rare but aggressive malignancy. Standard of Care for Pleural Mesothelioma Pleural … Continue reading Long-Term Mesothelioma Survival with ONCOS-102
COVID-19 Vaccine May Help Mesothelioma Survivors Avoid Serious Side Effects
Several new studies illustrate the importance of the COVID-19 vaccine for malignant mesothelioma patients and survivors. They suggest that people with mesothelioma would do well to find out the rules for vaccination in their state. In one study, cancer patients who contracted the SARS-CoV-2 (COVID) infection developed serious neurologic symptoms. These symptoms are rarely seen in healthy people who get the illness. Another study showed cancer survivors were more likely to get severely ill or die from SARS-CoV-2. The study says this is because they tend to have more underlying medical conditions. An article published in Cancer Discovery found that people with cancer die of SARS-CoV-2 at a rate twice as high as those without cancer. The COVID-19 vaccine may … Continue reading COVID-19 Vaccine May Help Mesothelioma Survivors Avoid Serious Side Effects
Radiotherapy Outcomes in Mesothelioma Linked to Metabolism
Italian researchers say metabolic markers may hold the key to predicting radiotherapy outcomes in people with mesothelioma. Metabolism is the process by which cells produce energy. Metabolism is necessary for cancer cells to live. Mesothelioma cells metabolize faster than healthy cells. Radiotherapy affects cancer cell metabolism. A new study shows that compounds produced during metabolism may impact radiotherapy outcomes. It suggests that a patient’s metabolic profile – or metabolome – could help doctors choose good candidates for radiation. Radical Hemithoracic Radiotherapy and Mesothelioma Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Metabolism
Standard Biomarkers for Pleural Mesothelioma “Not Useful” for Immunotherapy
Two of the most important biomarkers for pleural mesothelioma are not much help when it comes to tracking response to immunotherapy. Top mesothelioma researchers at the University of Pennsylvania drew that conclusion based on data from a cohort of 58 patients. They focused on two primary biomarkers for pleural mesothelioma: SMRP and fibulin-3. Doctors use both of these markers to diagnose and plan treatment for mesothelioma. The study confirms the correlation between these markers and mesothelioma tumor volume. But the Penn Medicine researchers say these biomarkers of pleural mesothelioma were “not useful” for measuring immunotherapy response. Understanding Biomarkers for Pleural Mesothelioma A biomarker is a substance produced by the body that indicates a biological process or condition. Most mesothelioma biomarkers … Continue reading Standard Biomarkers for Pleural Mesothelioma “Not Useful” for Immunotherapy
Autoimmune Disease and Mesothelioma: Will it Impact Survival?
A new lung cancer study suggests that having an autoimmune disease will not necessarily lead to shorter cancer survival. This could be good news for pleural mesothelioma patients suffering from autoimmune disorders. Pleural mesothelioma is a lung-related disease that has many characteristics in common with lung cancer. The new study comes from Northwestern University Feinberg School of Medicine in Chicago. It included 177 lung cancer patients who also had immune diseases. Doctors compared their survival with a control group of lung cancer patients. They determined that having an autoimmune disease did not negatively impact lung cancer survival. In fact, some of those patients lived longer than those with healthy immune systems. What is an Autoimmune Disease? An autoimmune disease is … Continue reading Autoimmune Disease and Mesothelioma: Will it Impact Survival?
WHO to Recognize Fourth Mesothelioma Subtype
The World Health Organization will soon recognize mesothelioma in situ as a fourth mesothelioma subtype. The 2015 WHO classification of pleural mesothelioma includes three histological subtypes. Pathologists can tell the difference between the subtypes by looking at the cells under a microscope. Each subtype has a slightly different cell shape, growth pattern, and nuclear characteristics. The proposed fourth mesothelioma subtype is a very early form of mesothelioma. Previous studies suggest that it may be a precursor to invasive mesothelioma. If patients know they have it, they may have years to try to keep mesothelioma from developing. Differences Between the Subtypes Pleural mesothelioma is a very rare type of cancer. Only about 2,500 people in the US receive a mesothelioma diagnosis … Continue reading WHO to Recognize Fourth Mesothelioma Subtype
Chemotherapy Resistance in Mesothelioma Patients: New Insights
Canadian cancer researchers have discovered what may be a key cause of chemotherapy resistance in mesothelioma and other types of cancer. The news could lead to more effective ways of treating malignant mesothelioma. Chemotherapy resistance is a major problem for mesothelioma patients. The FDA has approved two different drug therapies for mesothelioma. But neither approach seems to hold asbestos cancer at bay long term. Scientists at Princess Margaret Cancer Centre in Toronto say it may be because cancer cells “hibernate” to escape attack. If doctors can understand this cancer cell defense mechanism, they might be able to undermine it. The Problem of Chemotherapy Resistance Malignant mesothelioma is the most serious of several illnesses caused by exposure to asbestos. Asbestos fibers … Continue reading Chemotherapy Resistance in Mesothelioma Patients: New Insights
Mesothelioma and COVID-19 Have Similar Psychological Challenges
Researchers in Italy say malignant mesothelioma and COVID-19 present patients with similar psychological challenges. In both cases, group therapy may help. Malignant pleural mesothelioma is an aggressive cancer of the lung lining. COVID-19 is the respiratory illness caused by the SARS-CoV2 virus. The two illnesses may not seem to have much in common. But psychology researchers at the University of Turin say there are similarities between mesothelioma and COVID-19. They say understanding how mesothelioma affects patients psychologically could help providers support people with COVID-19. Coping with Pleural Mesothelioma and COVID-19 Pleural mesothelioma is usually the result of asbestos exposure. Most people who receive a mesothelioma diagnosis either worked with asbestos or lived near it. Many of them had no idea … Continue reading Mesothelioma and COVID-19 Have Similar Psychological Challenges
Predicting Mesothelioma Survival with Routine Clinical Tests
UK researchers say predicting mesothelioma survival does not have to be complicated. Their new study shows routine doctor’s office tests may be just as accurate as more complex metrics. The study appears in the new issue of the BMJ Open Respiratory Research journal. It involved 100 patients with malignant mesothelioma over a four-year period. The team compared treatment outcomes among these patients with their results on basic health tests. More often than not, these tests correctly predicted their prognosis. The researchers say simplifying the process of predicting mesothelioma survival could help doctors and patients make better treatment decisions. Prognostic Indicators in Asbestos Cancer Malignant pleural mesothelioma is an uncommon but lethal form of membrane cancer. Patients who get it usually … Continue reading Predicting Mesothelioma Survival with Routine Clinical Tests
Spread of Peritoneal Mesothelioma Slows with Apatinib
An investigational drug called apatinib may help stop the growth and spread of peritoneal mesothelioma. Chinese researchers recently tested the VEGF inhibitor on mice infected with human mesothelioma. They found that the spread of peritoneal mesothelioma slowed way down in the presence of apatinib. The drug worked in the lab and in live mice with few serious side effects. If larger experiments confirm apatinib’s effectiveness, the next step could be trials in human mesothelioma patients. Apatinib Blocks Blood Vessel Formation Apatinib is also known as Rivoceranib. It keeps cancer cells from using the protein VEGF. VEGF (vascular endothelial growth factor) allows tumors to spawn new blood vessels. A rich supply of fresh blood fuels the growth and spread of peritoneal … Continue reading Spread of Peritoneal Mesothelioma Slows with Apatinib
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!